NasdaqGS:PRAXBiotechs
Praxis Precision Medicines (PRAX) Valuation After FDA-Backed EMBRAVE3 Redesign for Elsunersen
Praxis Precision Medicines (PRAX) just cleared a key regulatory hurdle, wrapping up a Type C meeting with the FDA that reshapes its EMBRAVE3 trial for elsunersen into a leaner single arm design.
See our latest analysis for Praxis Precision Medicines.
The news around EMBRAVE3 lands on top of a powerful run, with Praxis delivering a roughly 44 percent 1 month share price return and a staggering 546 percent 3 month share price return, while its 1 year total shareholder return above 250 percent...